|
|
???tair.name??? >
???browser.page.title.author???
|
"nishiyama"???jsp.browse.items-by-author.description???
Showing items 1-5 of 5 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國立成功大學 |
2024-11 |
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri
|
Boku;Narikazu;Omori;Takeshi;Shitara;Kohei;Sakuramoto;Shinichi;Yamaguchi;Kensei;Kato;Ken;Kadowaki;Shigenori;Tsuji;Kunihiro;Ryu;Min-Hee;Oh;Do-Youn;Oh;Cheul, Sang;Rha;Young, Sun;Lee;Keun-Wook;Chung;Ik-Joo;Sym;Jin, Sun;Chen;Li-Tzong;Chen;Jen-Shi;Bai;Li-Yuan;Nakada;Takashi;Hagihara;Shunsuke;Makino;Reina;Nishiyama;Eiji;Kang;Yoon-Koo |
| 國立成功大學 |
2024-09 |
Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
|
Iwata;Hiroji;Xu;Binghe;Kim;Sung-Bae;Chung;Wei-Pang;Park;Hee, Yeon;Kim;Hwan, Min;Tseng;Ling-Ming;Chung;Chi-Feng;Huang;Chiun-Sheng;Kim;Hyun, Jee;Chiu;Yan, Joanne Wing;Yamashita;Toshinari;Li;Wei;Egorov;Anton;Nishijima;Soichiro;Nakatani;Shunsuke;Nishiyama;Yuji;Sugihara;Masahiro;Cortes;Javier;Im;Seock-Ah |
| 國立成功大學 |
2024-01 |
Controversies in terminology associated with management of BCG-unresponsive NMIBC in Asia-Pacific
|
Kikuchi;Eiji;Ng;Chi-Fai;Kitamura;Hiroshi;Ku;Hyeon, Ja;Lee;Shiong, Lui;Lin;Tzu-Ping;Ng;Siu, Junice Yi;Nishiyama;Hiroyuki;Poon;Darren, Ming-Chun;Kanesvaran;Ravindran;Seo;Kyung, Ho;Spiteri;Carmel;Tan;Min, Ee;Tsai;Yuh-Shyan;Tran;Ben |
| 國立成功大學 |
2024-01 |
Risk stratification and management of non-muscle-invasive bladder cancer: A physician survey in six Asia-Pacific territories
|
Ku;Hyeon, Ja;Lee;Shiong, Lui;Lin;Tzu-Ping;Kikuchi;Eiji;Kitamura;Hiroshi;Ng;Chi-Fai;Ng;Siu, Junice Yi;Poon;Darren, Ming-Chun;Kanesvaran;Ravindran;Seo;Kyung, Ho;Spiteri;Carmel;Tan;Min, Ee;Tran;Ben;Tsai;Yuh-Shyan;Nishiyama;Hiroyuki |
| 國立成功大學 |
2024 |
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3�tri
|
Boku;N;Omori;T;Shitara;K;Sakuramoto;S;Yamaguchi;K;Kato;K;Kadowaki;S;Tsuji;K;Ryu;M, -H.;Oh;D, -Y.;Oh;S, C.;Rha;S, Y.;Lee;K, -W.;Chung;I, -J.;Sym;S, J.;Chen;L, -T.;Chen;J, -S.;Bai;L, -Y.;Nakada;T;Hagihara;S;Makino;R;Nishiyama;E;Kang;Y, -K. |
Showing items 1-5 of 5 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
